disease (PD). Median patient's plasma levels of EGFR were 32.4 ng/ml. There were not differences in p according to histology, site of metastasis and ECOG. There were differences in response to therapy; CR+PR+SD p presented median EGFR of 31.97 ng/ml [13.2−48.6] vs 30 ng/ml [16.9−46.8] in the PD group (p = 0.024). Dividing the cohort in two sets according to EGFR median we found two significantly different groups in terms of Overall Survival (OS) and Time To Progression (TTP). Patients with EGFR32.4 ng/ml was 4.7 m [4.0−5.4], (p = 0.024). OS when EGFR32.4 ng/ml was 9.1 m [8.2−10.1], (p = 0.038).
Conclusions: Patients with PD presented significantly lower levels of serum EGFR than those patients with CR+PR+SD. There is a relationship among lower EGFR concentration in serum with a worst prognosis in advanced NSCLC p in terms of TTP and OS.

6592 POSTER

Determination of plasma K-ras mutations in codon 12 in advanced non-small cell lung cancer (NSCLC) patients. Analysis of its prognostic role

R. Sirera[1], C. Camps[1], R. García-Gomez[2], N. Viñolas[3], A. Artal[4], M. Guillot[5], A. Blasco[1], M.J. Safont[1], M. Taron[6], R. Rosell[6]. *[1]Hospital General Universitario, Oncologia Medica, Valencia, Spain; [2]Hospital Gregorio Marañon, Oncologia Medica, Madrid, Spain; [3]Hospital Clinic, Oncologia Medica, Barcelona, Spain; [4]Hospital Clinico Miguel Servet, Oncologia Medica, Zaragoza, Spain; [5]Hospital Son Dureta, Oncologia Medica, Palma de Mallorca, Spain; [6]Hospital Germans Trias i Pujol, Oncologia Medica, Badalona, Spain*

Background: Qualitative analysis of circulating DNA in blood is a promising non-invasive diagnostic and prognostic tool. Our aim was to study the association between the presence of K-ras mutations at codon 12 and several clinical variables in advanced NSCLC patients.
Materials and Methods: We examined 451 NSCLC patients in stage IIIB and IV, treated with cisplatin and docetaxel. Blood samples were collected before chemotherapy, and circulating DNA was extracted from the plasma using commercial adsorption columns. K-ras mutational status was determined by a method based in allelic discrimination with RT-PCR.
Results: Median age was 61 years [35−82] and 84% were males. 99% had performance status 0−1. 84% were in stage IV and 16% in stage IIIB. The histological subtypes were: 32% squamous cell carcinoma, 50% adenocarcinoma, 14% anaplastic large cell, and 4% undifferentiated. 41% of the patients received second line chemotherapy. 1% achieved complete response (CR), 36% partial response (PR), 35% had stable disease (SD) and 28% progressive disease (PD). Here we present the results of the analysis of K-ras mutations in the plasma of 165 samples. 17 patients presented K-ras mutations (10.3%), being codon 12 TGT in 16 patients and GTT in 1 case. Plasmatic mutations were found either in patients presenting squamous cell carcinoma (n = 3) and in patients with adenocarcinoma (14). Patients with K-ras mutations in plasma had a median time to progression (TTP) of 2.3 months (m) [0.5−4.6] while for wild type K-ras was 4.1 m [3.3−4.8], (p = 0.9). Overall Survival (OS) in K-ras mutated patients was 10.1 m [4.1−15.8] and in wild type K-ras was 9.0 m [6.9−11.1], (p = 0.6).
Conclusions: In advanced NSCLC, there were no significant differences between patients with K-ras mutations and those with wild-type genotype with respect to baseline characteristics, response rates, TTP, or OS. Data from the rest of the cohort will be presented at the meeting.

6593 POSTER

Nerve growth factor (NGF) levels in plasma in patients with advanced non-small cell lung cancer patients (NSCLC). Is it predictive of clinical outcome?

R. Sirera[1], C. Camps[1], C. Caballero[1], M.J. Safont[1], A. Blasco[1], J. Gavila[1], A. Cabrera-Pastor[1], V. Iranzo[1], M. Taron[2], R. Rosell[2]. *[1]Hospital General Universitario, Oncologia Medica, Valencia, Spain; [2]Hospital Germans Trias i Pujol, Oncologia Medica, Badalona, Spain*

Background: Platinum compounds and taxanes have severe side effects in a dose and time-dependent manner, especially neurotoxicity. NGF plays an important role in growth and differentiation of neuronal components. Our goal was to study NGF levels in plasma and correlate it with patient's clinico-pathologic characteristics.
Materials and Methods: The study was performed with 451 patients with advanced NSCLC, stages IIIB-IV and treated with cisplatin and docetaxel. Peripheral blood was collected before therapy. NGF were assessed by commercial ELISA (detection limit, 5 pg/ml). Plasma from 32 age and gender-matched controls was used.
Results: 91% of males, mean age 61 y [35−82]. 86 patients in ECOG PS 0−1 and 14 PS2. 71% in stage IV and 29% in IIIB. The histological subtypes were 38% squamous cell, 37% adenocarcinoma, 5% anaplasic large cell and 20% undifferentiated. 77.5% of the metastasis was out of the lung. Patients received a median of 6 cycles of chemotherapy [1−7]. 4% presented complete response (CR), 38% partial response (PR), 25% stable disease (SD) and 30% progressive disease (PD). Patient's median plasma levels of NGF did not differ significantly from controls: 44 pg/ml [6–176] vs 31 pg/ml [14–144] respectively. There were not differences according to histology, site of metastasis and ECOG; however we could observe significant differences with stage: 25 pg/ml [10−70] in stage IIIB vs 47 pg/ml [6–176] in stage IV (p = 0.008). We could not observe any differences in response to therapy: CR+PR patients presented median NGF of 35 pg/ml [6−92] vs 39 pg/ml [10–165] in the SD+PD group. Splitting the cohort according to NGF median we found two significantly different groups in terms of Overall Survival (OS): patients with NGF44 pg/ml (p = 0.03). In the multivariate analysis, NGF levels was not predictor for time to progression (TTP) and OS.
Conclusions: NGF plasma levels did not differ in patients and controls. In our cohort with advanced NSCLC we have not found any relationship between NGF levels with histology, response, site of metastasis and TTP. By contrast NGF levels are higher in those patients in stage IV and in those presenting poorer OS.

6594 POSTER

First-line bevacizumab in combination with chemotherapy in the treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): an open-label safety study (MO19390)

L. Crinò[1], E. Dansin[2], P. Garrido Lopez[3], F. Griesinger[4], J. Laskin[5], N. Pavlakis[6], N. Thatcher[7], C.M. Tsai[8], D. Stroyakovskiy[9], W.C. Su[10]. *[1]Azienda ospedaliera di Perugia, Department of Medical Oncology, Perugia, Italy; [2]CRLCC Oscar Lambret, Département de Cancérologie générale, Lille, France; [3]Hospital Ramon Y Cajal, Servicio de Oncología Médica, Madrid, Spain; [4]Pius-Hospital Oldenburg, Department of Radiation Therapy and Medical Oncology, Oldenburg, Germany; [5]University of British Columbia, Division of medical Oncology., Vancouver, Canada; [6]University of Sydney, Faculty of Medicine, Sydney, Australia; [7]Christie Hospital NHS Trust, Department of Medical Oncology, Manchester, United Kingdom; [8]Taipei Veterans General Hospital, Section of Thoracic Oncology Chest Department, Taipei, Taiwan; [9]Moscow City Clinical Oncology Hospital, Moscow, Russian Federation; [10]National Cheng Kung University Hospital, Department of Hematology and Oncology, Tainan, Taiwan*

Background: Bevacizumab, a humanised monoclonal antibody that inhibits VEGF, improves survival of patients with advanced or recurrent NSCLC when used first-line in combination with carboplatin/paclitaxel [Sandler et al. NEJM 2006]. MO19390 is an open-label, single arm, multicentre study investigating the safety profile of bevacizumab in combination with standard first-line chemotherapy.
Methods: Approximately 2000 patients will receive bevacizumab (15 mg/kg q3w) plus standard first-line chemotherapy (investigator choice) for a maximum of 6 cycles. Non-progressing patients will receive bevacizumab monotherapy until disease progression or unacceptable toxicity. The primary endpoint is the safety profile of bevacizumab when combined with first-line chemotherapy. Secondary endpoints include time to disease progression and overall survival. Eligible patients must have histologically or cytologically documented inoperable, locally advanced, metastatic or recurrent non-squamous NSCLC, ECOG PS 0–2 and adequate haematological, liver and renal function. Patients with a history of haemoptysis, evidence of tumour invading major blood vessels or evidence of CNS metastases are excluded. During treatment, the incidence of all serious and non-serious adverse events will be monitored, irrespective of their association with bevacizumab. Information about adverse events of special interest will also be reported.
Results: As of March 2007, 306 patients have been enrolled. Safety data are available for 202 patients; 62.4% are male and the median age is 59 years. Other patient characteristics (%) include: non-smoker/ex- or current-smoker 69/31 (no data <1); ECOG PS 0/1/2 39.8/53.7/6.5 (no data <1); chemotherapy backbone: cisplatin–gemcitabine/carboplatin–paclitaxel / carboplatin–gemcitabine / cisplatin–paclitaxel / monotherapy / non-platinum doublets/other 30.2/23.8/12.9/5.9/3.5/1.5/22.2. To date, a total of 87 serious adverse events (SAEs) have been reported, 18 of which are considered by the investigator to be associated with the study drug. SAEs of special interest reported to date are 4 thromboembolic events, 1 congestive heart failure and 3 bleeding events (2 epistaxis and 1 other haemorrhage). No haemoptysis SAEs have been reported to date.
Conclusions: The large population size will provide valuable information on the safety profile of bevacizumab and will allow investigation of non-frequent adverse events. Updated safety data will be discussed.